-transparent.png){kind=logo}
The synthesis of 5'-substituted thalidomide analogs is described. The amino acids 2 necessary to synthesize the target compounds were prepared by Michael reaction. Condensation of 2 with phthalic anhydrides followed by reaction with urea yielded 4 as diastereomeric mixtures. Furthermore glutethimide (5) was brominated by an improved method and the resulting compound 6 was reacted in several steps with sodium azide, hydrogen, and phthalic anhydride to give 8. In a similar manner, 6 was reacted with sodium azide and various phthalic anhydrides to give 9, 10, and 11. All final compounds were tested in vitro for their inhibitory activity on the release of TNF-alpha, using stimulated peripheral mononuclear blood cells (PBMCs). Compounds with an additional aromatic substituent in position 5' of the thalidomide molecule were more active than thalidomide. Compound 11 was able to reduce increased levels of IL-2 in vitro.
U Teubert, and
K Zwingenberger, and
S Wnendt, and
K Eger
June 1999,
Bioorganic & medicinal chemistry letters,
U Teubert, and
K Zwingenberger, and
S Wnendt, and
K Eger
February 2007,
Chemical & pharmaceutical bulletin,
U Teubert, and
K Zwingenberger, and
S Wnendt, and
K Eger
November 2021,
Pharmaceutics,
U Teubert, and
K Zwingenberger, and
S Wnendt, and
K Eger
July 1991,
Antimicrobial agents and chemotherapy,
U Teubert, and
K Zwingenberger, and
S Wnendt, and
K Eger
October 2003,
Bioorganic & medicinal chemistry letters,
U Teubert, and
K Zwingenberger, and
S Wnendt, and
K Eger
January 1996,
Chirality,
U Teubert, and
K Zwingenberger, and
S Wnendt, and
K Eger
December 1996,
Clinical immunology and immunopathology,
U Teubert, and
K Zwingenberger, and
S Wnendt, and
K Eger
January 1986,
Lymphokine research,
U Teubert, and
K Zwingenberger, and
S Wnendt, and
K Eger
July 2005,
Leukemia,
U Teubert, and
K Zwingenberger, and
S Wnendt, and
K Eger
January 2004,
Acta neurobiologiae experimentalis,
